medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 1

<< Back Next >>

Ann Hepatol 2016; 15 (1)

Early allograft dysfunction after liver transplantation: an intermediate outcome measure for targeted improvements

Lee DD, Croome KP, Shalev JA, Musto KR, Sharma M, Keaveny AP, Taner CB

Language: English
References: 26
Page: 53-60
PDF size: 150.37 Kb.


ABSTRACT

Background. The term early allograft dysfunction (EAD) identifies liver transplant (LT) allografts with initial poor function and portends poor allograft and patient survival. Aims of this study are to use EAD as an intermediate outcome measure in a large single center cohort and identify donor, recipient and peri-operative risk factors. Material and methods. In 1950 consecutive primary LT, donor, recipient and peri-operative data were collected. EAD was defined by the presence of one or more of the following: total bilirubin ≥ 10 mg/dL (171 µmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST ‹ 2,000 IU/L within the first 7 days. Results. The incidence of EAD was 26.5%. 1-, 3-, and 5-year allograft and patient survival for patients who developed EAD were significantly inferior to those who did not (P ‹ 0.01 at all time points). Multivariate analysis demonstrated associations in the development of EAD with recipient pre-operative ventilator status, donation after cardiac death allografts, donor age, allograft size, degree of steatosis, operative time and intra-operative transfusion requirements (all P ‹ 0.01). Patients with EAD had a significantly longer hospitalization at 20.9 ± 38.9 days (median: 9; range: 4-446) compared with 10.7 ± 13.5 days (median: 7; range: 3-231) in patients with no EAD (P ‹ 0.01). Conclusions. This is the largest single center experience demonstrating incidence of EAD and identifying factors associated with development of EAD. EAD is a useful intermediate outcome measure for allograft and patient survival. Balancing recipient pretransplant conditions, donor risk factors and intra-operative conditions are necessary for avoiding EAD.


REFERENCES

  1. Deschênes M, Belle SH, Krom RA, Zetterman RK, Lake JR. Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation 1998; 66: 302-10.

  2. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transplantation 2010; 16: 943-9.

  3. Croome KP, Hernandez-Alejandro R, Chandok N. Early allograft dysfunction is associated with excess resource utilization after liver transplantation. Transplant Proceedings 2013; 45: 259-64.

  4. Camci C, Akdogan M, Gurakar A, Gilcher R, Rose J, Monlux R, Alamain S, et al. The impact of total plasma exchange on early allograft dysfunction. Transplant Proceedings 2004; 36: 2567-9.

  5. Deschenes M. Early allograft dysfunction: causes, recognition, and management. Liver Transplantation 2013; 19: S6-S8.

  6. Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, Hancock WW, et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transplantation 2012; 18: 166-76.

  7. Hoyer DP, Paul A, Gallinat EP, Reinhardt R, Minor T, Saner FH, Canbay A, et al. Donor information based prediction of early allograft dysfunction and outcome in liver transplantation. Liver International 2015; 35: 156-63.

  8. Cortes M, Pareja E, García-Canaveras JC, Donato MT, Montero S, Mir J, Castel JV, et al. Metabolomics, discloses donor liver biomarkers associated with early allograft dysfunction. J Hepatology 2014; 61: 564-74.

  9. Taner CB, Bulatao IG, Willingham DL, Perry DK, Sibulesky L, Pungpapong S, Aranda-Michel J, et al. Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors. Liver Transplantation 2012; 18: 100-11.

  10. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-90.

  11. Ploeg RJ, D’Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, Saaki T, et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993; 55: 807-13.

  12. Hong JC, Kaldas FM, Kositamongkol P, Petrowsky H, Farmer DG, Markovic D, Hiatt JR, et al. Predictive index for long-term survival after retransplantation of the liver in adult recipients: analysis of a 26-year experience in a single center. Ann Surg 2011; 254: 444-8.

  13. Salvalaggio PR, Felga GE, Afonso RC, Ferraz-Neto BH. Early allograft dysfunction and liver transplant outcomes: a single center retrospective study. Transplant Proceedings 2012; 44(8): 2449-51.

  14. Wagener G, Raffel B, Young AT, Minhaz M, Emond J. Predicting early allograft failure and mortality after liver transplantation: the role of the postoperative model for end-stage liver disease score. Liver Transplantation 2013; 19: 534-42.

  15. Hong SH, Kwak JA, Jeon JY, Park CS. Prediction of early allograft dysfunction using serum phosphorous level in living donor liver transplantation. Transplant International 2013; 26: 402-10.

  16. McDiarmid SV, Anand R, Martz K, Milis MJ, Mazariegos G. A multivariate analysis of Pre-, Peri-, and Post-transplant factors affecting outcome after pediatric liver transplantation. Ann Surg 2011; 254: 145-54.

  17. Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, Hancock WW, et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transplantation 2012; 18: 166-76.

  18. Guarrera JV, Henry SD, Samstein B, Reznik E, Musat C, Lukose TI, Ratner LE, et al. Hypothermic machine preservation facilitates successful transplantation of “orphan” extended criteria donor livers. Am J Transplant 2015; 15: 161-9.

  19. Vogel T, Brockmann JG, Coussios C, Friend PJ. The role of normothermic extracorporeal perfusion in minimizing ischemia reperfusion injury. Transplant Reviews (Orlando) 2012; 26: 156-62.

  20. Jamieson RW, Zilvetti M, Roy D, Hughes D, Morovat A, Coussios CC, Friend PJ. Hepatic steatosis and normothermic perfusion- preliminary experiments in a porcine model. Transplantation 2011; 92: 289-95.

  21. Lee DD, Singh A, Burns JM, Perry DK, Nguyen JH, Taner CB. Early allograft dysfunction in liver transplantation using donation after cardiac death donors results in inferior survival. Liver Transplantation 2014; 20: 1447-53.

  22. Saidi RF, Bradley J, Greer D, Luskin R, O’Connor K, Delmonico F, Kennealey P, et al. Changing Pattern of Organ Donation at a Single Center: Are Potential Brain Dead Donors Being Lost to Donation After Cardiac Death? Am J Transplant 2010; 10: 2536-40.

  23. Biancofiore G, Bindi ML, Romanelli AM, Bisà M, Boldrini A, Consani G, Filipponi F, et al. Postoperative intra-abdominal pressure and renal function after liver transplantation. Arch Surg 2003; 7: 703-6.

  24. Lai JC, Feng S, Roberts JP. An examination of liver offers to candidates on the liver transplant wait-list. Gastroenterology 2012; 143: 1261-5.

  25. Barshes NR, Horwitz IB, Franzini L, Vierling JM, Goss JA. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant 2007; 7: 1265-70.

  26. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. N Eng J Med 2009; 361: 1368-75.




2020     |     www.medigraphic.com